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Human cytosolic sialidase (Neuraminidase 2, NEU2) catalyzes the removal of terminal sialic acid residues
from glycoconjugates. The effect of siastatin B, known as a sialidase inhibitor, has not been evaluated
toward human NEU2 yet. We studied the regulation of NEU2 activity by siastatin B in vitro and predicted
the interaction in silico. Inhibitory and stabilizing effects of siastatin B were analyzed in comparison with
DANA (2-deoxy-2,3-dehydro-N-acetylneuraminic acid) toward 4-umbelliferyl N-acetylneuraminic acid
(4-MU-NANA)- and α2,3-sialyllactose-degrading activities of recombinant NEU2 produced by E. coli GST-
fusion gene expression. Siastatin B exhibited to have higher competitive inhibitory activity toward NEU2
than DANA at pH 4.0. We also revealed the stabilizing effect of siastatin B toward NEU2 activity at acidic
pH. Docking model was constructed on the basis of the crystal structure of NEU2/DANA complex (PDB
code: 1VCU). Molecular docking predicted that electrostatic neutralization of E111 and E218 residues of
the active pocket should not prevent siastatin B from binding at pH 4.0. The imino group (1NH) of
siastatin B can also interact with D46, neutralized at pH 4.0. Siastatin B was suggested to have higher
afﬁnity to the active pocket of NEU2 than DANA, although it has no C7–9 fragment corresponding to that
of DANA. We demonstrated here the pH-dependent afﬁnity of siastatin B toward NEU2 to exhibit potent
inhibitory and stabilizing activities. Molecular interaction between siastatin B and NEU2 will be utilized
to develop speciﬁc inhibitors and stabilizers (chemical chaperones) not only for NEU2 but also the other
human sialidases, including NEU1, NEU3 and NEU4, based on homology modeling.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Sialidases (neuraminidases) are exo-glycosidases, which cata-
lyze the initial step of catabolism of sialylglycoconjugates by hy-
drolyzing the terminal non-reducing sialic acid residues from the
oligosaccharides attached to glycoproteins and glycolipids, and
have marked effects on the biological functions of these glyco-
conjugates [1,2]. There are four human neuraminidases (NEUs)
different in their enzymatic properties including substrate speci-
ﬁcities and pH optima [1,3]. They are also classiﬁed based on their
major subcellular distributions as intralysosomal NEU1, cytosolic
NEU2, plasma membrane NEU3 and mitochondria/lysosomal
NEU4. The four human NEUs have the unique amino acidB.V. This is an open access article u
h).sequences common to the sialidase family, including the arginine
triad [1,2,4], Asp box [1,2,5], and RIP motif [6]. The sequence
identity (average) among NEUs2–4 is 34 (75.2)%, although that of
NEU1 with NEUs2–4 [23 (70.4)%] is relatively low. At present, the
crystal structure of NEU2 is the only one elucidated among them
[7], which is utilized for homology modeling for other NEUs [8,9].
Sialidase inhibitors have been applied as a useful tool to char-
acterize the catalytic activities including substrate speciﬁcity, and
elucidate their biological functions and disease processes [10].
DANA, as a sialic acid transition-state analog, is a well-used in-
hibitor and exhibits moderate inhibitory activity toward a variety
of sialidases, although it is not selective for inﬂuenza virus neur-
aminidases with Ki values in micromolar range [11,12] compared
to those of zanamivir (Relenza) and oseltamivir (Tamiﬂu) in na-
nomolar range [13–17]. The inhibitory effects of DANA toward
human NEU2 were also reported by Magesh et al. [9] and Chavasnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Siastatin B is a sialidase inhibitor, initially isolated from a Strep-
tomyces strain and identiﬁed as 6-acetamido-3-piperidine car-
boxylate structurally similar to sialic acid (N-acetylneuraminic
acid) [18]. Siastatin B has broad spectra and inhibits sialidases
isolated from various microorganisms, animal tissues and viruses
[18–20]. The charge distribution in siastatin B as a zwitterion re-
sembles that in the N-acetylneuraminate oxocarbenium ion as the
putative intermediate form in the enzyme-catalyzed reaction. This
feature may account for its binding to the active pockets of siali-
dases and inhibitory activity [19]. Siastatin B has been also re-
ported to have the inhibitory effects toward mammalian sialidases
with IC50 values in the mM range including cytosolic sialidases
puriﬁed from rat liver and skeletal muscle cells, although the
sensitivities of sialidases to the inhibitor differ dependently on
species [18]. However, the effect of siastatin B toward human
NEU2 has not been evaluated yet. In this study, we ﬁrst demon-
strated the inhibitory effects of siastatin B in vitro toward re-
combinant human NEU2. The pH dependency of inhibitory activity
of siastatin B was also examined in comparison with that of DANA.
We also found the stabilizing property of siastatin B toward hu-
man NEU2 under acidic pH conditions. Moreover, we also per-
formed molecular docking of siastatin B as to the active pocket of
human lysosomal NEU1 model based on the three-dimensional
structure of NEU2. Relationship between inhibitory and stabilizing
potency of siastatin B, and interaction with amino acid residues
located around active pocket of NEU2 and NEU1 model was also
discussed.2. Materials and methods
2.1. Substrates and inhibitors
4-Methylumbelliferyl-N-acetyl-α-D-neuraminic acid (4-MU-
NANA) was purchased from Nacalai Tesque, Inc. (Kyoto, Japan).
α2,3-Sialyllactose was purchased from Sigma-Aldrich (St. Louis,
MO). Siastatin B and DANA were purchased from Peptide Institute,
Inc. (Osaka, Japan) and Calbiochem (CA), respectively.
2.2. Expression and puriﬁcation of recombinant human NEU2
Expression and puriﬁcation of NEU2 proteins had been de-
scribed elsewhere [20]. Brieﬂy, E. coli Origami B cells (Takara, To-
kyo, Japan) were transformed with plasmid pGEX-2 T-NEU2, and
the transformed cells were grown in LB-ampicillin(þ) medium at
37 °C until the optical density became 0.6 before the addition of
isopropyl-α-D-thiogalactopyranoside (IPTG). After 40 h growth at
27.5 °C in the presence of 0.1 mM IPTG, cells were harvested by
centrifugation and suspended in phosphate-buffered saline (PBS).
The cells were then lysed in PBS (pH 7.4) by sonication, and a
supernatant was obtained by centrifugation during which Triton
X-100 was added to a ﬁnal concentration of 1%. The resultant su-
pernatant containing the GST-NEU2 fusion proteins was applied to
a GSH-Sepharose (GE Healthcare, Uppsala, Sweden) afﬁnity chro-
matography column equilibrated with PBS (pH 7.4) containing 1%
Triton X-100. Cleavage of the thrombin-recognition sequence lo-
cated between the GST and NEU2 in fusion proteins was carried
out by adding 100 mL of a thrombin solution comprising 1 IU in
PBS, and then incubating the column for 16 h at 22 °C. The eluted
NEU2 was further applied to a diethylaminoethyl (DEAE)-Sephar-
ose ion exchange chromatography column equilibrated with
10 mM sodium phosphate buffer (pH 8.0) containing 1 M NaCl,
and the NEU2 proteins were eluted as the pass-through fraction
using an AKTA apparatus (GE Healthcare). The crude cell lysate
and fractions obtained during the puriﬁcation procedures wereassayed for NEU2 activity, and the protein concentration of each
fraction was also determined according to the method of Lowry
[21]. The purity of the enzyme fraction was determined by SDS-
PAGE [22] and Coomassie brilliant blue (CBB R-350) staining.
Western blotting was performed to analyze the molecular
weight of puriﬁed monomeric NEU2, protein samples were sub-
jected to SDS-PAGE on a 10% acrylamide gel. The protein was
transferred to polyvinylidine diﬂuoride membrane (Millipore
Billerica, MA). On immunoblotting, membrane was incubated with
50% (v/v) Blocking One (Nacalai Tesque, Japan) in Tris-buffered
saline (TBS) (pH 7.4) for 2 h at room temperature. The membrane
was treated with anti-NEU2 rabbit polyclonal antibody (Sigma St.
Louis, MO, USA) diluted with Blocking One/TBS (1:1,000 dilutions)
overnight at 4 °C. After washing with TBS containing 0.1% Tween
20, the membrane was treated with horseradish peroxidase-con-
jugated anti-rabbit IgG (1:1,000 dilution) (Sigma) as secondary
antibodies for 1 h at room temperature. After washing with same
buffer, detection of antibody binding was carried out with ECL
(PerkinElmer Inc. MA) according to the manufacturer's
instructions.
2.3. Enzyme and inhibition assaying of recombinant human NEU2
NEU2 enzyme activity was measured using the synthetic sub-
strate 4-MU-NANA by ﬂuorimetric assay [20]. Routinely, the re-
action mixture (40 μL) was composed of 8 μL of 0.2 M sodium
acetate buffer (pH 4.0 or pH 6.0), 2 μL of 50 mg/mL bovine serum
albumin (BSA), 5 μL of 2 mM 4-MU-NANA, 20 μL of an appro-
priately diluted inhibitor solution and 5 μL of recombinant human
NEU2. In the inhibition assay for NEU2, the enzyme activity in this
mixture was maintained at 9.5 nmol/30 min/5 μL. After incubation
for 30 min at 37 °C, 770 μL of glycine–NaOH (pH 10.7) was added
to stop the reaction. The ﬂuorescence of the released 4-methy-
lumbelliferone (4-MU) was measured using a spectroﬂuorometer
(Fluoroskan ascent microplate ﬂuorometer, Finland) at 360 nm
(excitation) and 455 nm (emission). The concentration causing
50% inhibition (IC50) of each inhibitor for NEU2 activity also de-
termined. To evaluate the mode of inhibition by each inhibitor, the
concentration of inhibitor versus the reaction rate was plotted, and
Ki value was determined by the method of Lineweaver and Burk
[23].
The NEU2 activity toward α2,3-sialyllactose was determined by
an improved Warren method [24] using sialic acid assay kit (Ab-
nova, Taiwan, Version: 03), in which sialic acid is oxidized to for-
mylpyruvic acid, which reacts with thiobarbituric acid to form a
pink colored product. The color intensity at 549 nm is directly
proportional to sialic acid concentration in the sample. Reactions
were set up for positive control sample by using 5 mg of puriﬁed
NEU2, in 25 mM of sodium-citrate-phosphate buffer at pH 4.0 and
or 6.0, containing 50 mg of α-(2,3) sialyllactose in a ﬁnal volume of
100 mL (0.75 mM ﬁnal concentration) [25]. The inhibitory effects of
siastatin B and DANA toward NEU2 were measured in the presence
of 600 mM inhibitors in a ﬁnal volume of 100 mL. After incubation
at 37 °C for 1 h, total sialic acid (bound sialic acid) and released
sialic acid (hydrolyzed sialic acid) were determined according to
the procedures recommended by the manufacturer.
2.4. In vitro stabilization assay for NEU2 by siastatin B and DANA
Puriﬁed NEU2 proteins (8 mg/mL) were pre-incubated in 0.1 M
sodium phosphate buffers at various pH at 37 °C with or without
siastatin B or DANA for several time intervals. Pre-incubation was
terminated by the addition of two volumes of 0.2 M sodium
phosphate buffer (pH 6.0) and kept on ice immediately before
enzyme assay. The enzyme activity was determined at pH 6.0 with
4-MU-NANA as the substrate.
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Molecular docking of siastatin B to NEU2 was performed on the
basis of X-ray crystal structure of human NEU2 in complex with
the inhibitor DANA (PDB-ID: 1VCU) at pH 4.0 and 6.0, which in-
volved three steps: calculation of protein ionization of NEU2 at pH
4.0 and 6.0, ligand binding prediction of siastatin B, and binding
free energy calculation. Protein ionization of NEU2 at pH 4.0 and
6.0 was predicted using Discovery Studio 3.1 (Accelrys, Inc.) uti-
lizing the theory developed by Bashford and Karplus [26]. Results
from assignment of ionization states of titratable amino acids in
NEU2, following amino acids were protonated at pH 4.0: E10, E39,
E50, D58, E72, E111, D131, D141, E153, E218, E223, D251, D254,
E257, D336, D345, E360, E361 and E376, and at pH 6.0: D336. Two
pH-dependent models of NEU2/DANA complex were reﬁned for
ligand docking and binding energy calculation using the Protein
Preparation Wizard Script within Maestro (Schrödinger, LLC).
Siastatin B was docked into the reference position of the DANA of
DANA/NEU2 complex models at pH 4.0 and pH 6.0 using the Glide
ver. 5 SP mode (Schrödinger, LLC) [27]. Finally, the binding en-
ergies between each ligand and NEU2 for at pH 4.0 and pH
6.0 were estimated using CHARMm based energies and implicit
solvation methods on Discovery Studio 3.1. Moleculer docking of
siastatin B was also performed as to the human NEU1 model
constructed by homology modeling using two reference proteins,
human NEU2 and bacterial sialidase from Micromonospora0.0
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Fig. 1. Analysis of puriﬁed recombinant human NEU2 produced by E. coli (Origami B
puriﬁcation, after DEAE column chromatography (lane 1) and eluate treated with throm
with CBB R350. (B) Western blot analysis of puriﬁed protein samples, the molecular we
described under “Materials and methods” (lane 1) and biotinylated protein standards (lan
as described under “Section 2”.viridifaciens [28]. Using the model, calculation of protein ionization
of NEU1 at pH 4.0, ligand binding prediction of siastatin B and
binding free energy calculation were performed according to the
above docking procedure for NEU2.3. Results
3.1. Puriﬁcation of recombinant human NEU2 produced by Escher-
ichia coli gene expression system
In order to obtain a large amount of recombinant human NEU2
protein, we expressed the GST-NEU2 fusion gene with pGEX-2 T
vector in E. coli (Origami B strain) as described under Section 2. As
shown in Fig. 1(A), the puriﬁed protein appeared as a single band
on SDS-PAGE, with an apparent molecular mass of about 42 kDa,
indicating a high degree of purity. In addition, the 42-kDa protein
was immunostained by using anti-NEU2 antibody on western
blotting (Fig. 1(B)). Puriﬁed NEU2 exhibited 4-MU-NANA-degrad-
ing activity under broad pH conditions (pH 4.0–6.5) with optimal
pH range (5.5–6.0) (Fig. 1(C)). The speciﬁc activities were 5.19 at
pH 6.0, and 3.59 μmol/min/mg protein at pH 4.0. The Km and
apparent Vmax values were 0.45 mM and 38.8 μmol/min/mg
protein at pH 6.0, and 0.28 mM and 26.5 μmol/min/mg protein at
pH 4.0, respectively.4.5 5 5.5 6 6.5 7 7.5
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strain) gene expression system. (A) SDS-PAGE of the fractions obtained during
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ight of the monomeric NEU2 (42 kDa) detected by speciﬁc polyclonal antibody as
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Fig. 2. Structures of siastatin B (6-acetamido-3-piperidine carboxylate) [18] (A) and DANA (2-deoxy-2,3-dehydro-N-acetylneuraminic acid) [11] (B). M.F.: Molecular formula;
M.W.: Molcular weight. Inhibitory effects of siastatin B (6-acetamido-3-piperidine carboxylate) and DANA (2,3-didehydro-2-deoxy-N-acetylneuraminic acid) on 4MU-NANA-
degrading activity of recombinant human NEU2 at pH 6.0 (C) and pH 4.0 (D), and on α2,3-sialyllactose-degrading activity at pH 6.0 and 4.0 (E).
Table 1
Inhibitory effects of siastatin B and DANA toward recombinant human NEU2.
Inhibitor IC50(lM) Ki(lM) Binding free energy (kcal/mol)
pH 4.0 pH 6.0 pH 4.0 pH 6.0 pH 4.0 pH 6.0
Siastatin B 71.0 284 150 250 117 108
DANA 146 69.0 360 100 83.9 143
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NEU2
We ﬁrst examined the inhibitory effects of siastatin B in vitrotoward NEU2 activity as to the artiﬁcial substrate 4-MU-NANA as
well as natural substrate α2,3-sialyllactose. Fig. 2(A and B) shows
the structures of siastatin B and DANA, respectively, tested in this
study. As shown in Fig. 2(C), DANA exhibited the dose-dependent
inhibition of NEU2 activity at pH 6.0 as previously reported [9].
Siastatin B also had the inhibitory effect on NEU2, although the
efﬁcacy was less than that of DANA at pH 6.0. In contrast, siastatin
B exhibited remarkable dose-dependent inhibition of NEU2 at pH
4.0, while DANA had less effect (Fig. 2(D)). IC50 values for siastatin
B and DANA toward 4-MU-NANA-degrading activity, as summar-
ized in Table 1, were 284 mM and 69 mM at pH 6.0, while 71 mM
and 146 mM at pH 4.0, respectively. At pH 4.0 siastatin B inhibited
89% of NEU2 activity at 300 mM concentration, whereas DANA did
Table 2
Inhibitory effects of siastatin B and DANA toward recombinant human NEU2 as to
the natural substrate α2,3-sialyllactosea.
Sample pH Sialic acid Relative rate of hydrolysis (%)
Bound Released
mmol
NEU2 6.0 885 808 100
4.0 867 769 100
NEU2/siastatin Bb 6.0 866 387 47.8
4.0 890 277 36.1
NEU2/DANAb 6.0 855 336 41.6
4.0 882 494 64.3
a Substrate was incubated for 1 h under the standard assay conditions.
b Siastatin B and DANA: ﬁnal concentration 600 mM.
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of siastatin B inhibited 56%, whereas DANA did 79% under the
same experimental conditions. At higher pH range (7.0–7.5), DANA
inhibited NEU2 more strongly (data not shown).
The modes of inhibition by siastatin B were competitive at both
pH 4.0 and 6.0, similar to those by DANA [9]. The Ki values of
siastatin B and DANA at different pHs were summarized in Table 1.
At pH 6.0 the Ki value for siastatin B was 250 mM, which was 2.5-
fold higher than DANA (100 mM). In contrast, the Ki value for0
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Fig. 3. In vitro stabilization of NEU2 by siastatin B and DANA. Thermostability of 4-MU
sodium acetate buffer at pH 6.0 (●), 5.0 (■) or 4.0 (Δ) at 37 °C for different time intervals
4.0) in the presence of siastatin B (B) and DANA (C) at different concentrations of 50 mMsiastatin B (150 mM) was 2.4-fold lower than that for DANA
(360 mM) at pH 4.0.
NEU2 activity toward a natural substrate α2,3- sialyllactose was
also demonstrated to be inhibited by siastatin B (Fig. 2(E)). As
shown in Table 2, NEU2 had released sialic acid from α2,3- sia-
lyllactose in an average 808 mmol/h at pH 6.0 and 769 mmol/h at
pH 4.0, whereas, the bound sialic acid (sialic acid content) was in
an average 884.81 mmol. Siastatin B and DANA both at 600 mM
concentration inhibited 52% and 58% of NEU2 activity at pH
6.0 toward α2,3-sialyllactose, respectively. In comparisons, these
values at lower acidic pH 4.0 were 64% and 36%, respectively, for
siastatin B and DANA both at the same concentration.
3.3. Stabilizing effects of siastatin B toward recombinant Human
NEU2
Fig. 3 shows the effect of siastatin B on thermostability of NEU2
activity in vitro. The puriﬁed NEU2 was pre-incubated at 37 °C for
indicated time at pH 6.0, pH 5.0 and pH 4.0, respectively, and then
the remaining enzyme activity was assayed at pH 6.0 with 4-MU-
NANA as a substrate. The puriﬁed NEU2 activity produced by E. coli
(Origami B strain) was found to be thermostable after pre-in-
cubation at pH 6.0 and pH 5.0, but was lost substantially at pH 4.0
(Fig. 3(A)). During pre-incubation at pH 4.0 siastatin B stabilized
NEU2 activity dose-dependently. After pre-incubation with
100 mM and 200 mM of siastatin B at pH 4.0 for 1 h at 37 °C, NEU20 40 50 60
tion time (min)
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-NANA-degrading activity of puriﬁed human NEU2 after pre-incubation in 0.1 M
(A). Residual NEU2 activity after pre-incubation in 0.1 M sodium acetate buffer (pH
(Δ), 100 mM (■), 200 mM (●) or 0 (○) mM.
Fig. 4. Molecular docking of the DANA and siastatin B to the active pocket of NEU2 based on the crystal structure of the NEU2/DANA complex (PDB code: 1VCU) without
steric hindrance. Protonation of amino acid residues is indicated around inhibitor binding site compared at pH 4.0 and pH 6.0. Comparison of binding manners of DANA at pH
4.0 (A) and pH 6.0 (B). pH-dependent neutralization of E111 is predicted to have inﬂuence on binding of DANA C7–9 fragment (dashed oval). The E218 interacts with R237 via
ionic bond. Neutralization of E218 may possibly have the effect on local structure of NEU2 supporting the binding of DANA C7–9 fragment. Comparison of binding manners of
siastatin B at pH 4.0 (C) and pH 6.0 (D). There is no chemical groups in siastatin B corresponding to those of DANA C7–9 fragment, which may not inﬂuence the interaction
between siastatin B and the neutralized amino acid residues (E111 and E218, dashed circle) at pH 4.0. The imino group (1NH) can interact with D46, which is not inﬂuenced
by neutralization at pH 4.0.
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spectively (Fig. 3(B)). In contrast, DANA had no stabilizing effects at
pH 4.0 on puriﬁed NEU2 at any concentrations tested in this ex-
periment (Fig. 3(C)).
3.4. Molecular docking of siastatin B as to the active pockets of hu-
man NEU2 and NEU1 model
In order to predict the molecular interaction between siastatin
B and NEU2, the docking model of siastatin B as to the active
pocket of NEU2 was constructed on the basis of the X-ray crystal
structure of NEU2/DANA complex (PDB code: 1 VCU). The in silico
conditions under which an almost unique conﬁguration with the
least steric conﬂict and proper hydrogen bonds should be formed
between siastatin B and amino acid residues located around the
active pocket were also screened as described in “Section 2”. The
local structure and protonation of amino acid residues around
inhibitor binding site of NEU2 were compared at pH 4.0 and pH
6.0, respectively (Fig. 4(A–D)). The carboxyl groups of E111 andE218 residues around the active pocket were predicted to be
electrostatically neutralized at pH 4.0. As for the whole molecule
of NEU2, only the D336 is neutralized at pH 6.0 in contrast to E10,
E39, E50, D58, E72, E111, D131, D141, E153, E218, E223, D251, D254,
E257, D336, D345, E360, E361 and E376 at pH 4.0. The binding
manners of DANA to the active pocket of NEU2 were compared at
pH 4.0 and pH 6.0 (Fig. 4(A and B)). It was predicted that the pH-
dependent neutralization at E111 and E218 could reduce the
binding afﬁnity of the C7–9 fragment of DANA through inﬂuencing
the local structure of active pocket necessary for the binding of the
DANA fragment (Fig. 4(A and B)). Higher binding afﬁnity of DANA
at pH 6.0 was also suggested by the calculated binding energy at
pH 6.0 (Table 1). In contrast, siastatin B exhibited relatively higher
afﬁnity toward the active pocket of NEU2 at pH 4.0, although it
lacks chemical fragment corresponding to the C7–9 fragment of
DANA, which should be necessary for interaction with E111 and
E218, as shown in Fig. 4(C and D). Additionally, the imino group
(1NH) should interact with the side chain of D46, which was also
not inﬂuenced by neutralization at pH 4.0. The stabilizing effect of
Fig. 5. Molecular docking of the siastatin B as to the active pocket of human lysosomal sialidase NEU1. (A) Predicted binding manners of siastatin B as to the active pocket of
NEU1 model based on 3D-structure of human NEU2 and bacterial sialidase of M. viridifaciens. (B) Sequence alignment between human NEU2 and NEU1. Amino acid residues
colored cyan indicate the putative binding site with siastatin B at acidic pH 4.0. Dashed ovals are shown as in (A) corresponding to those indicated by red squares are shown
as in (B).
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supported by the calculated binding energy at pH 4.0 (Table 1).
We also predicted the interaction between siastatin B and hu-
man lysosomal NEU1 with acidic pH optimum by the molecular
docking of siastatin B as to the active pocket of NEU1 model, which
was constructed as described under “Section 2”. Fig. 5(A) shows
the binding manners of siastatin B as to the active pocket of NEU1
model at acidic pH 4.0. Results from assignment of ionization
states of tritratable amino acids in homology model of human
NEU1 predicted that the following amino acids were protonated at
pH 4.0: E61, D75, E95, E104, D130, D135, D145, E147, D176, D190,
E194, D226, D263, E264, E269, D300, D306, E312, D315, E377,
D381, E383 and E384. Note the amino acid numbers were deﬁned
in case of the N-terminal methionine of human NEU1 precursor
protein containing leader sequence as one (M1). Fig. 5(B) shows
the putative binding sites with siastatin B at pH4.0. The D103 inNEU1 model corresponding to the D46 in NEU2 was predicted to
interact with the imino group (1NH) of siastatin B, which was also
not inﬂuenced by neutralization at pH 4.0, while the D263 was
electrostatically neutralized at pH 4.0 but bound to siastatin B,
although the D263 was adjacent to the E264 in NEU1 model cor-
responding to the L217 of NEU2 adjacent to the E218. The binding
afﬁnity of siastatin B as to the active pocket of NEU1 model was
also supported by the calculated binding free energy of siastatin B
(113.91 kcal/mol) at pH 4.0.4. Discussion
In this study, we demonstrated for the ﬁrst time the inhibitory
effects of siastatin B toward recombinant human NEU2 in vitro (IC50
value, 284 mM at pH 6.0). In previous reports, siastatin B was
M.M. Rahman et al. / Biochemistry and Biophysics Reports 4 (2015) 234–242 241demonstrated to inhibit bacterial, viral and mammalian sialidases at
different concentrations ranged from mM to mM [18,29,30]. It in-
hibits bacterial sialidases with the IC50 values, which ranges from 27
to 80 mM [15,16] and viral sialidases in the 10 mM range [31].
Umezawa et al. demonstrated that the IC50 values toward cytosolic
sialidase from rat mammary gland, brain and liver, were 0.99, 3.60
and 1.53 mM, respectively [18]. In contrast, Miyagi et al. reported
that siastatin B had less inhibitory activity against partially puriﬁed
cytosolic sialidase from rat liver and skeletal muscle [10].
Interestingly, the inhibitory activity of siastatin B against hu-
man NEU2 was more potent under acidic pH conditions (IC50,
71 mM at pH 4.0) compared to that under higher pH conditions
(IC50, 284 mM at pH 6.0) in this study. DANA is a well-known se-
lective inhibitor for human NEU2 and exhibits inhibitory potency
at around neutral pH [7,9]. Lower inhibitory effects of DANA were
reported toward acidic sialidases including human lysosomal
NEU1 compared to that of cytosolic human NEU2 [9,32]. In this
study we observed the lower efﬁcacy of DANA toward human
NEU2 at acidic pH (IC50, 146 mM at pH 4.0) than that at higher pH
(IC50, 69 mM at pH 6.0).
The mode of inhibition of siastatin B against human NEU2 was
competitive as to the substrate 4-MU-NANA at pH 4.0 (Ki, 150 mM)
and pH 6.0 (Ki, 250 mM). Similar inhibition mechanism by siastatin
B was reported against bacterial sialidases at around pH 6.0 with a
range of Ki value from 17 to 43 mM as to the sialolactose [18]. The
lower Ki value (150 mM) of siastatin B at acidic pH indicated higher
afﬁnity of siastatin B to the active pocket of human NEU2, whereas
lower afﬁnity of DANA toward NEU2 was observed at pH 4.0, as
shown by 2.4-fold higher Ki value (360 mM) than siastatin B (Ki,
150 mM) (Table 1). These results suggested higher inhibitory po-
tency of siastatin B toward human NEU2 compared to that of
DANA under acidic pH conditions.
Docking model of the NEU2/siastatin B complex was con-
structed on the basis of NEU2/ DANA crystal structure for predic-
tion of molecular interaction between siastatin B and the active
pocket of NEU2 at different pHs. The residues D46, E111 and E218
of NEU2 were reported to be crucial for substrate binding and
catalytic activity as an enzymatic acid–base catalyst during hy-
drolysis thereby facilitating the coordination of the inhibitor [4,5].
A recent study by comparative analysis of the active sites of sia-
lidases derived from different sources along with NEU2 conﬁrmed
the role of the E218 as member of the nucleophile pair (334Y/
218E) essential for catalysis [25]. Here we also predicted that the
protonation of amino acid residues of NEU2, including E10, E39,
E50, D58, E72, E111, D131, D141, E153, E218, E223, D251, D254,
E257, D336, D345, E360, E361 and E376, by in silico analysis as the
electrostatically neutralized residues at pH 4.0. Among them, E111
and E218 residues located around the active pocket. The E111 re-
sidue could be involved in the coordination of the C7–9 chemical
fragment of DANA inﬂuenced by pH-dependent neutralization.
The E218 can also interact with R237 via ionic bond. The neu-
tralization of E218 may possibly have effect on local structure of
the active pocket of NEU2 supporting the binding of C7–9 frag-
ment of DANA. The binding energy of DANA (142.69 kcal/mol) at
pH 6.0 and (83.91 kcal/mol) at pH 4.0 suggested more stable
binding of DANA at pH 6.0 compared at pH 4.0. On the other hand,
the neutralization at pH 4.0 may not inﬂuence the interaction
between siastatin B and the active pocket of NEU2 because there
are no chemical groups in siastatin B corresponding to those of
DANA C7–9 fragment. Additionally, the D46 of NEU2 coordinated
the imino group (1NH) of siastatin B, which should also not be
inﬂuenced by neutralization at pH 4.0, although the binding en-
ergy (107.58 kcal/mol) for siastatin B at pH 6.0 is not so different
from 111.66 kcal/mol at pH 4.0. In order to conﬁrm the con-
tribution of the E111 residue to the interaction predicted by
docking models, we tried to produce the recombinant mutantNEU2 by site-directed mutagenesis causing single substitution
E111A. However, the NEU2 mutant (E111A) had completely lost the
catalytic activity toward 4-MU-NANA (data not shown). Mozzi
et al. reported NEU2 (E218A) mutant had little catalytic activity
[25]. Therefore, we could not validate the prediction of the roles of
E111 and E218 at acidic pH.
In this study we revealed that the human NEU2 produced by E.
coli (Origami B strain) exhibits striking thermostability at pH 6.0 at
least for 60 min but not at pH4.0, suggesting it can retain the
proper folding and active conformation at pH 6.0 but lose at pH
4.0. Interestingly, siastatin B had stabilizing activity toward NEU2,
which exhibit catalytic function under acidic conditions (pH 4.0–
5.5), probably by preventing NEU2 protein from denaturation at
acidic pH. The interaction between imino group (1NH) of siastain B
and the active pocket of NEU2 including the D46 may also be in-
volved in the stabilizing effect.
Homology modeling studies on not only human NEUs based on
amino acid sequence identity and the crystal structure of NEU2 but
also viral and bacterial sialidases, suggest structural similarity
among NEU2, NEU3 and NEU4 [3,8,17] and different undelying
mechanisms of inhibitors on these sialidases. Hata et al. reported
that the inhibition of oseltamivir (Tamiﬂu) and zanamivir (Re-
lenza) of inﬂuenza viral sialidases N1–3 at the nanomolar levels,
while they exhibited the limited inhibitory effects on human sia-
lidases including NEU1-4, although zanamivir had a little in-
hibitory effect of NEU2 at the micromolar level (16.4 μM at pH 5.5)
[16]. We previously predicted using ab initio MO calculations [17]
that DANA with the C4–OH group possibly interacts with the E111
of NEU2 due to hydrogen bonding, and the positively charged
guanidino group of zanamivir is also involved in electrostatic in-
teractions with the E39 and D46 in NEU2, which may be re-
sponsible for the inhibitory effects on NEU2 activity. In contrast,
the active form of oseltamivir with NH3þ group at the corre-
sponding position does not exhibit the inhibitory effect on NEU2
because it is not able to form a hydrogen bond to the E111 of NEU2.
On the other hand, oseltamivir has remarkable inhibitory activity
towards inﬂuenza viral sialidase N1-NA [16] because of the pos-
sible electrostatic interaction between the NH3þ group and the
negatively charged E119 of N1-NA (PDB ID: 2HU4) [17]. As the
amino acid residues E113 and E225 of NEU3 as well as E111 and
E222 of NEU4 corresponding to E111 and E218 of NEU2, respec-
tively are conserved by homology modeling [3]. Interactions with
these glutamic acid residues of NEUs in pH-dependent manner
should be considered on molecular design of inhibitor and stabi-
lizer (chemical chaperone) based on the chemical structures of
DANA derivatives.
In this study, we observed reverse inhibitory effects between
DANA and siastatin B towards NEU2 at pH 6.0 and 4.0. At pH 6.0,
the hydrogen bonding interaction between the C4–OH group of
DANA and the E111 of NEU2 as well as the C7–9 fragment of DANA
and the E218 of NEU2 may be reduced at pH 4.0. In contrast, the
local interactions at the active pocket of NEU2, especially between
the imino (1NH) group of siastatin B and the D46 of NEU2, may
become stronger even at pH 4.0 than those at pH 6.0. Here we also
predicted that siastatin B could bind to the active pocket of human
lysosomal NEU1 model because the local conformation around the
active pocket should be similar to that of NEU2. Siastatin B was
suggested to interact with not only the D103 but also the D263 and
E264 residues of NEU1 model, corresponding to the D46, L217 and
E218 in NEU2, although the E111 in NEU2 was replaced with the
A162 in NEU1 model. Therefore, siastatin B may have inhibitory
effect on NEU1 at pH 4.0. Siastatin B derivatives retaining the
imino group (1NH) will be seed compounds for more speciﬁc in-
hibitors and stabilizers for variety of sialidases, including mam-
malian, microbial and viral origins, by comparison of the pH-de-
pendent effects of siastatin B.
M.M. Rahman et al. / Biochemistry and Biophysics Reports 4 (2015) 234–242242In conclusion, we found the pH-dependent afﬁnity of siastatin
B toward human cytosolic sialidase NEU2 to exhibit potent in-
hibitory and stabilizing activities. It was supported by molecular
docking that the interaction between siastatin B and the D46, E111
and E218 in the active pocket of NEU2 should be the key amino
acid residues regulating the enzymatic functions of NEU2 espe-
cially at acidic pH.Acknowledgments
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